Bedard PL, Jhaveri KL, Accordino MK, Cervantes PA, et al. Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. Eur J Cancer 2025;221:115397.
PMID: 40203765